Large waist circumference and a specific genetic variation may be accurate predictors of an increased risk for metabolic syndrome in children prescribed second-generation antipsychotics. Medscape Medical News
No Comments »
Filed under: General Health News
A new study has found traces of parabens in breast cancer tumors. Do they play a role in the development of cancer? Medscape Medical News
No Comments »
Filed under: General Health News
WASHINGTON (MedPage Today) — The delay is over for the diabetes drug Bydureon (exenatide extended-release), with FDA approval making it the first once-weekly treatment for type 2 disease.
No Comments »
Filed under: General Health News
WASHINGTON (MedPage Today) — Medicare doesn’t adequately track which physicians are opting out of Medicare, making it nearly impossible to determine who is cutting ties with the program and why, according to an OIG memo.
No Comments »
Filed under: General Health News
(MedPage Today) — The impact that motor vehicle exhaust has on asthma costs is much bigger than once thought, researchers warned.
No Comments »
Filed under: General Health News
(MedPage Today) — An FDA proposal to require dietary supplement manufacturers to submit data proving their product is safe doesn’t go far enough, one expert charged.
No Comments »
Filed under: General Health News
(MedPage Today) — What should be done about controversial research on the H5N1 avian flu that some think should be suppressed and others think has important benefits that should be pursued?
No Comments »
Filed under: General Health News
(MedPage Today) — Large numbers of Americans who should have screening exams for breast, colon, and cervical cancer are not getting them, government researchers said.
No Comments »
Filed under: General Health News
WASHINGTON (MedPage Today) — The delay is over for the diabetes drug Bydureon (exenatide extended-release), with FDA approval making it the first once-weekly treatment for type 2 disease.
No Comments »
Filed under: Pharmacy News
(MedPage Today) — Another angiogenesis blocker, axitinib (Inlyta), has won FDA approval as a second-line treatment for advanced kidney cancer, the agency said Friday.
No Comments »
Filed under: Pharmacy News
